Table of Contents Author Guidelines Submit a Manuscript
Canadian Respiratory Journal
Volume 2017, Article ID 8184915, 10 pages
https://doi.org/10.1155/2017/8184915
Research Article

The Burden of Illness Related to Chronic Obstructive Pulmonary Disease Exacerbations in Québec, Canada

1GlaxoSmithKline, Research Triangle Park, Durham, NC, USA
2GlaxoSmithKline, Mississauga, ON, Canada
3JSS Medical Research Inc., Saint Laurent, QC, Canada
4Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, ON, USA
5GlaxoSmithKline, Collegeville, PA, USA
6McGill University, Montreal, QC, Canada

Correspondence should be addressed to John S. Sampalis; moc.hcraeserssj@snoissimbus

Received 18 January 2017; Revised 11 April 2017; Accepted 15 May 2017; Published 20 June 2017

Academic Editor: Angelo G. Corsico

Copyright © 2017 Tam Dang-Tan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Statistics Canada, Chronic obstructive pulmonary disease in Canadians, 2009 to 2011, 2016, http://www.statcan.gc.ca/pub/82-625-x/2012001/article/11709-eng.htm.
  2. J. Evans, Y. Chen, P. G. Camp, D. M. Bowie, and L. McRae, “Estimating the prevalence of COPD in Canada: reported diagnosis versus measured airflow obstruction,” Health Reports, vol. 25, no. 3, pp. 3–11, 2014. View at Google Scholar · View at Scopus
  3. Canadian Institute for Health Information, Health Indicators, Ottawa, Ontario, Canada, 2004.
  4. N. Mittmann, L. Kuramoto, S. J. Seung, J. M. Haddon, C. Bradley-Kennedy, and J. M. FitzGerald, “The cost of moderate and severe COPD exacerbations to the Canadian healthcare system,” Respiratory Medicine, vol. 102, no. 3, pp. 413–421, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. M. Doucet, L. Rochette, and D. Hamel, “Incidence, Prevalence, and Mortality Trends in Chronic Obstructive Pulmonary Disease over 2001 to 2011: A Public Health Point of View of the Burden,” Canadian Respiratory Journal, vol. 2016, Article ID 7518287, 2016. View at Publisher · View at Google Scholar · View at Scopus
  6. M. Miravitlles, C. Murio, T. Guerrero, and R. Gisbert, “Pharmacoeconomic evaluation of acute exacerbations of chronic bronchitis and COPD,” Chest, vol. 121, no. 5, pp. 1449–1455, 2002. View at Publisher · View at Google Scholar · View at Scopus
  7. J. B. Oostenbrink and M. P. M. H. Rutten-van Mölken, “Resource use and risk factors in high-cost exacerbations of COPD,” Respiratory Medicine, vol. 98, no. 9, pp. 883–891, 2004. View at Publisher · View at Google Scholar · View at Scopus
  8. J. F. O'Reilly, A. E. Williams, and L. Rice, “Health status impairment and costs associated with COPD exacerbation managed in hospital,” International Journal of Clinical Practice, vol. 61, no. 7, pp. 1112–1120, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. T. R. Schermer et al., “Exacerbations and associated healthcare cost in patients with COPD in general practice,” Monaldi Arch Chest Dis, vol. 65, no. 3, pp. 133–140, 2006. View at Google Scholar
  10. A. Anzueto, “Impact of exacerbations on copd,” European Respiratory Review, vol. 19, no. 116, pp. 113–118, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Miravitlles, M. Ferrer, À. Pont et al., “Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: A 2 year follow up study,” Thorax, vol. 59, no. 5, pp. 387–395, 2004. View at Publisher · View at Google Scholar · View at Scopus
  12. K. Nishimura, S. Sato, M. Tsukino et al., “Effect of exacerbations on health status in subjects with chronic obstructive pulmonary disease,” Health and Quality of Life Outcomes, vol. 7, article no. 69, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. A. Anzueto, I. Leimer, and S. Kesten, “Impact of frequency of COPD exacerbations on pulmonary function, health status and clinical outcomes.,” International journal of chronic obstructive pulmonary disease, vol. 4, pp. 245–251, 2009. View at Google Scholar · View at Scopus
  14. J. A. Wedzicha and G. C. Donaldson, “Exacerbations of chronic obstructive pulmonary disease,” Respiratory Care, vol. 48, no. 12, pp. 1204–1213, 2003. View at Google Scholar · View at Scopus
  15. T. A. Seemungal, G. C. Donaldson, A. Bhowmik, D. J. Jeffries, and J. A. Wedzicha, “Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease,” American Journal of Respiratory and Critical Care Medicine, vol. 161, no. 5, pp. 1608–1613, 2000. View at Publisher · View at Google Scholar · View at Scopus
  16. T. A. Seemungal, G. C. Donaldson, E. A. Paul, J. C. Bestall, D. J. Jeffries, and J. A. Wedzicha, “Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease,” American Journal of Respiratory and Critical Care Medicine, vol. 157, no. 5, pp. 1418–1422, 1998. View at Publisher · View at Google Scholar · View at Scopus
  17. P. M. Calverley, J. A. Anderson, B. Celli et al., “Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease,” New England Journal of Medicine, vol. 356, no. 8, pp. 775–789, 2007. View at Publisher · View at Google Scholar · View at Scopus
  18. M. E. Charlson, P. Pompei, K. L. Ales, and C. R. MacKenzie, “A new method of classifying prognostic comorbidity in longitudinal studies: development and validation,” Journal of Chronic Diseases, vol. 40, no. 5, pp. 373–383, 1987. View at Publisher · View at Google Scholar · View at Scopus
  19. W. D'Hoore, A. Bouckaert, and C. Tilquin, “Practical considerations on the use of the Charlson comorbidity index with administrative data bases,” Journal of Clinical Epidemiology, vol. 49, no. 12, pp. 1429–1433, 1996. View at Publisher · View at Google Scholar · View at Scopus
  20. F. Andersson, S. Borg, S.-A. Jansson et al., “The costs of exacerbations in chronic obstructive pulmonary disease (COPD),” Respiratory Medicine, vol. 96, no. 9, pp. 700–708, 2002. View at Publisher · View at Google Scholar · View at Scopus
  21. A. Dalal, “Direct costs of chronic obstructive pulmonary disease among managed care patients,” International Journal of Chronic Obstructive Pulmonary Disease, vol. 5, pp. 341–349, 2010. View at Publisher · View at Google Scholar
  22. J. M. FitzGerald, J. M. Haddon, C. Bradley-Kennedy et al., “Resource use study in COPD (RUSIC): A prospective study to quantify the effects of COPD exacerbations on health care resource use among COPD patients,” Canadian Respiratory Journal, vol. 14, no. 3, pp. 145–152, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. J. Vestbo, D. Leather, N. Diar Bakerly et al., “Effectiveness of fluticasone furoate-vilanterol for COPD in clinical practice,” New England Journal of Medicine, vol. 375, no. 13, pp. 1253–1260, 2016. View at Publisher · View at Google Scholar · View at Scopus
  24. Y. Lacasse, V. M. Montori, C. Lanthier, and F. Maltais, “The validity of diagnosing chronic obstructive pulmonary disease from a large administrative database,” Canadian Respiratory Journal, vol. 12, no. 5, pp. 251–256, 2005. View at Publisher · View at Google Scholar · View at Scopus
  25. A. Ismaila, D. Corriveau, J. Vaillancourt et al., “Impact of adherence to treatment with fluticasone propionate/salmeterol in asthma patients,” Current Medical Research and Opinion, vol. 30, no. 7, pp. 1417–1425, 2014. View at Publisher · View at Google Scholar · View at Scopus
  26. P. W. Jones, R. Lamarca, F. Chuecos et al., “Characterisation and impact of reported and unreported exacerbations: Results from ATTAIN,” European Respiratory Journal, vol. 44, no. 5, pp. 1156–1165, 2014. View at Publisher · View at Google Scholar · View at Scopus
  27. Régie de l'assurance maladie, “The Régie,” Historical Background, 2003, http://www.ramq.gouv.qc.ca/en/regie/pages/historical-background.aspx.
  28. R. Tamblyn, G. Lavoie, L. Petrella, and J. Monette, “The use of prescription claims databases in pharmacoepidemiological research: The accuracy and comprehensiveness of the prescription claims database in Québec,” Journal of Clinical Epidemiology, vol. 48, no. 8, pp. 999–1009, 1995. View at Publisher · View at Google Scholar · View at Scopus
  29. M. C Cyr, M. F. Beauchense, C. Lemiere, and L. Blais, “Comparison of the adherence and persistence to inhaled corticosteroids among adult patients with public and private drug insurance plans,” Journal of Population Therapeutics and Clinical Pharmacology, vol. 20, pp. e26–e41, 2013. View at Google Scholar
  30. R. Guanella, T. Ducruet, M. Johri et al., “Economic burden and cost determinants of deep vein thrombosis during 2 years following diagnosis: A prospective evaluation,” Journal of Thrombosis and Haemostasis, vol. 9, no. 12, pp. 2397–2405, 2011. View at Publisher · View at Google Scholar · View at Scopus
  31. A. Ismaila, D. Corriveau, J. Vaillancourt et al., “Impact of adherence to treatment with tiotropium and fluticasone propionate/salmeterol in chronic obstructive pulmonary diseases patients,” Current Medical Research and Opinion, vol. 30, no. 7, pp. 1427–1436, 2014. View at Publisher · View at Google Scholar · View at Scopus